bluebird bio, Inc. (BLUE) Shares Down 8.7%
bluebird bio, Inc. (NASDAQ:BLUE)’s share price fell 8.7% during trading on Monday . The stock traded as low as $119.90 and last traded at $125.45. 2,070,076 shares traded hands during trading, an increase of 118% from the average session volume of 947,998 shares. The stock had previously closed at $137.35.
A number of equities analysts have commented on BLUE shares. Zacks Investment Research cut shares of bluebird bio from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. BidaskClub downgraded shares of bluebird bio from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Jefferies Group LLC restated a “buy” rating and set a $88.00 target price on shares of bluebird bio in a research report on Friday, August 11th. Morgan Stanley cut shares of bluebird bio from an “equal weight” rating to an “underweight” rating and set a $105.00 target price on the stock. in a research report on Monday. Finally, Wedbush reaffirmed an “outperform” rating on shares of bluebird bio in a report on Tuesday, June 6th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $109.61.
The company’s market cap is $5.81 billion. The company has a 50-day moving average of $118.73 and a 200-day moving average of $100.09.
bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.66) by ($0.07). The business had revenue of $16.70 million during the quarter, compared to analyst estimates of $6.29 million. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The business’s revenue for the quarter was up 977.4% on a year-over-year basis. During the same period last year, the company earned ($1.59) EPS. On average, analysts forecast that bluebird bio, Inc. will post ($6.77) earnings per share for the current fiscal year.
In other bluebird bio news, Director Daniel Lynch sold 500 shares of bluebird bio stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $120.00, for a total transaction of $60,000.00. Following the completion of the sale, the director now directly owns 3,300 shares in the company, valued at $396,000. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Philip D. Gregory sold 2,250 shares of bluebird bio stock in a transaction dated Thursday, July 6th. The shares were sold at an average price of $103.83, for a total transaction of $233,617.50. Following the sale, the insider now owns 33,734 shares of the company’s stock, valued at $3,502,601.22. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 128,829 shares of company stock worth $15,480,499. 3.90% of the stock is owned by insiders.
Several hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. boosted its position in shares of bluebird bio by 5.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,600 shares of the biotechnology company’s stock worth $378,000 after purchasing an additional 191 shares during the period. Fairfield Bush & CO. acquired a new stake in bluebird bio in the 2nd quarter valued at approximately $210,000. Raymond James Financial Services Advisors Inc. acquired a new stake in bluebird bio in the 2nd quarter valued at approximately $211,000. The Manufacturers Life Insurance Company increased its holdings in bluebird bio by 0.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,433 shares of the biotechnology company’s stock valued at $3,302,000 after purchasing an additional 151 shares during the last quarter. Finally, Alpine Global Management LLC acquired a new stake in bluebird bio in the 2nd quarter valued at approximately $410,000.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.